The family of Interleukin-17 (IL-17) cytokine is the essential inflammatory mediator that influences the pathophysiology of various inflammatory diseases. Many studies focused on investigating the expression, signaling, and biological impacts of IL-17A and IL-17F, and the neutralization of these cytokines exhibited some promising results in clinical trials. In contrast, the expression resources and physiological relevance of IL-17C remained to be studied. In this study, through a microarray approach conducted with nontransformed human colonic epithelial cells (NCM460), we found that bacterial flagellin stimulation elicited potent IL-17C mRNA expression. We also confirmed that IL-17C protein production was strongly induced by flagellin in these cells. Flagellin-induced IL-17C expression was also observed in human colon adenocarcinoma cells such as DLD-1 and HT-29, indicating that IL-17C could be a signature inflammatory cytokine from intestinal epithelial cells in response to flagellin. Since inhibited in TLR5-, or MyD88- or TRIF-silenced cells, flagellin-induced IL-17C expression was specifically mediated by TLR5 and, subsequently, MyD88 and TRIF adaptor molecules. Furthermore, in line with inflammatory nature of IL-17, we found that IL-17C expression was substantially enhanced in the intestinal tissues from Ulcerative colitis patients. Given the facts that TLR5 is a key pattern recognition receptor which mediates microbial recognition in the intestinal epithelium and IL-17C turned out to be a unique member of the IL-17 family expressed in intestinal epithelial cells on TLR5 activation, our study may provide an important clue on understanding how intestinal microbes would contribute to an inflammatory program in the gut.
Get full access to this article
View all access options for this article.
References
1.
BlohmkeCJ, VictorRE, HirschfeldAF, EliasIM, HancockDG, LaneCR, DavidsonAG, WilcoxPG, SmithKD, OverhageJ, HancockRE, TurveySE. 2008. Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. J Immunol, 180,11:7764–7773.
2.
BurdelyaLG, KrivokrysenkoVI, TallantTC, StromE, GleibermanAS, GuptaD, KurnasovOV, FortFL, OstermanAL, DidonatoJA, FeinsteinE, GudkovAV. 2008. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science, 320,5873:226–230.
3.
CarvalhoFA, BarnichN, SauvanetP, DarchaC, GelotA, Darfeuille-MichaudA. 2008. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel Dis, 14,8:1051–1060.
ChoiYJ, ImE, PothoulakisC, RheeSH. 2010b. TRIF modulates TLR5-dependent responses by inducing proteolytic degradation of TLR5. J Biol Chem, 285,28:21382–21390.
6.
DorsamST, Vomhof-DekreyE, HermannRJ, HaringJS, Van der SteenT, WilkersonE, BoskovicG, DenvirJ, DementievaY, PrimeranoD, DorsamGP. 2010. Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells. Mol Immunol, 47,6:1181–1194.
7.
FeuilletV, MedjaneS, MondorI, DemariaO, PagniPP, GalanJE, FlavellRA, AlexopoulouL. 2006. Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci U S A, 103,33:12487–12492.
8.
FranchiL, AmerA, Body-MalapelM, KannegantiTD, OzorenN, JagirdarR, InoharaN, VandenabeeleP, BertinJ, CoyleA, GrantEP, NunezG. 2006. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol, 7,6:576–582.
9.
FujinoS, AndohA, BambaS, OgawaA, HataK, ArakiY, BambaT, FujiyamaY. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 52,1:65–70.
10.
GaffenSL. 2011. Recent advances in the IL-17 cytokine family. Curr Opin Immunol, 23,5:613–619.
11.
GenoveseMC, Van den BoschF, RobersonSA, BojinS, BiaginiIM, RyanP, Sloan-LancasterJ. 2010. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum, 62,4:929–939.
12.
GewirtzAT, Vijay-KumarM, BrantSR, DuerrRH, NicolaeDL, ChoJH. 2006. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am J Physiol Gastrointest Liver Physiol, 290,6:G1157–G1163.
13.
HuangW, NaL, FidelPL, SchwarzenbergerP. 2004. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis, 190,3:624–631.
14.
HueberW, PatelDD, DryjaT, WrightAM, KorolevaI, BruinG, AntoniC, DraelosZ, GoldMH, DurezP, TakPP, Gomez-ReinoJJ, FosterCS, KimRY, SamsonCM, FalkNS, ChuDS, CallananD, NguyenQD, RoseK, HaiderA, Di PadovaF. 2010. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med, 2,52:52ra72.
15.
ImE, ChoiYJ, PothoulakisC, RheeSH. 2009. Bacillus polyfermenticus ameliorates colonic inflammation by promoting cytoprotective effects in colitic mice. J Nutr, 139,10:1848–1854.
16.
IvisonSM, HimmelME, HardenbergG, WarkPA, KifayetA, LevingsMK, SteinerTS. 2010. TLR5 is not required for flagellin-mediated exacerbation of DSS colitis. Inflamm Bowel Dis, 16,3:401–409.
17.
KaoCY, KimC, HuangF, WuR. 2008. Requirements for two proximal NF-kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway epithelium. J Biol Chem, 283,22:15309–15318.
18.
KumarCK, MoyerMP, DudejaPK, SaidHM. 1997. A protein-tyrosine kinase-regulated, pH-dependent, carrier-mediated uptake system for folate in human normal colonic epithelial cell line NCM460. J Biol Chem, 272,10:6226–6231.
19.
LetranSE, LeeSJ, AtifSM, Flores-LangaricaA, UematsuS, AkiraS, CunninghamAF, McSorleySJ. 2011. TLR5-deficient mice lack basal inflammatory and metabolic defects but exhibit impaired CD4 T cell responses to a flagellated pathogen. J Immunol, 186,9:5406–5412.
20.
LiC, WongWH. 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A, 98,1:31–36.
21.
LiX, HansenPA, XiL, ChandraratnaRA, BurantCF. 2005. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor gamma and retinoic acid X receptors. J Biol Chem, 280,46:38317–38327.
22.
LodesMJ, CongY, ElsonCO, MohamathR, LandersCJ, TarganSR, FortM, HershbergRM. 2004. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest, 113,9:1296–1306.
23.
MiaoEA, Andersen-NissenE, WarrenSE, AderemA. 2007. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol, 29,3:275–288.
24.
MoyerMP, ManzanoLA, MerrimanRL, StaufferJS, TanzerLR. 1996. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell Dev Biol Anim, 32,6:315–317.
25.
PappuR, Ramirez-CarrozziV, SambandamA. 2011. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology, 134,1:8–16.
26.
PericM, KoglinS, KimSM, MorizaneS, BeschR, PrinzJC, RuzickaT, GalloRL, SchauberJ. 2008. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes. J Immunol, 181,12:8504–8512.
Ramirez-CarrozziV, SambandamA, LuisE, LinZ, JeetS, LeschJ, HackneyJ, KimJ, ZhouM, LaiJ, ModrusanZ, SaiT, LeeW, XuM, CaplaziP, DiehlL, de VossJ, BalazsM, GonzalezLJr., SinghH, OuyangW, PappuR. 2011. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol, 12,12:1159–1166.
29.
RayRM, McCormackSA, JohnsonLR. 2001. Polyamine depletion arrests growth of IEC-6 and Caco-2 cells by different mechanisms. Am J Physiol Gastrointest Liver Physiol, 281,1:G37–G43.
30.
RheeSH, ImE, PothoulakisC. 2008. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology, 135,2:518–528.
31.
RheeSH, ImE, RieglerM, KokkotouE, O'BrienM, PothoulakisC. 2005. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci U S A, 102,38:13610–13615.
32.
RheeSH, KeatesAC, MoyerMP, PothoulakisC. 2004. MEK is a key modulator for TLR5-induced interleukin-8 and MIP3alpha gene expression in non-transformed human colonic epithelial cells. J Biol Chem, 279,24:25179–25188.
33.
RheeSH, KimH, MoyerMP, PothoulakisC. 2006. Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J Biol Chem, 281,27:18560–18568.
34.
RodriguesNR, RowanA, SmithME, KerrIB, BodmerWF, GannonJV, LaneDP. 1990. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A, 87,19:7555–7559.
35.
RowanAJ, LamlumH, IlyasM, WheelerJ, StraubJ, PapadopoulouA, BicknellD, BodmerWF, TomlinsonIP. 2000. APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”Proc Natl Acad Sci U S A, 97,7:3352–3357.
36.
SaijoS, IkedaS, YamabeK, KakutaS, IshigameH, AkitsuA, FujikadoN, KusakaT, KuboS, ChungSH, KomatsuR, MiuraN, AdachiY, OhnoN, ShibuyaK, YamamotoN, KawakamiK, YamasakiS, SaitoT, AkiraS, IwakuraY. 2010. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity, 32,5:681–691.
37.
SchaeferTM, DesouzaK, FaheyJV, BeagleyKW, WiraCR. 2004. Toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology, 112,3:428–436.
38.
SeidererJ, ElbenI, DiegelmannJ, GlasJ, StallhoferJ, TillackC, PfennigS, JurgensM, SchmechelS, KonradA, GokeB, OchsenkuhnT, Muller-MyhsokB, LohseP, BrandS. 2008. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis, 14,4:437–445.
SongX, ZhuS, ShiP, LiuY, ShiY, LevinSD, QianY. 2011. IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol, 12,12:1151–1158.
41.
TarganSR, LandersCJ, YangH, LodesMJ, CongY, PapadakisKA, VasiliauskasE, ElsonCO, HershbergRM. 2005. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology, 128,7:2020–2028.
42.
Vijay-KumarM, AitkenJD, CarvalhoFA, CullenderTC, MwangiS, SrinivasanS, SitaramanSV, KnightR, LeyRE, GewirtzAT. 2010. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science, 328,5975:228–231.
Vijay-KumarM, SandersCJ, TaylorRT, KumarA, AitkenJD, SitaramanSV, NeishAS, UematsuS, AkiraS, WilliamsIR, GewirtzAT. 2007. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest, 117,12:3909–3921.
45.
YuJE, De RavinSS, UzelG, LandersC, TarganS, MalechHL, HollandSM, CaoW, HarpazN, MayerL, Cunningham-RundlesC. 2011. High levels of Crohn's disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease. Clin Immunol, 138,1:14–22.
